Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alcon, an eye care company, has said that its affiliate Alcon Laboratories, has signed a five-year contract with LCA-Vision, a provider of fixed-site laser vision correction services.
Subscribe to our email newsletter
Under the contract, LCA will place Allegretto Wave Eye-Q 400Hz excimer lasers in all of the company’s 75 LasikPlus vision surgery centers by the end of the third quarter of 2009. The contract comes as part of a decision by LCA to standardize its laser surgery technology on two laser platforms based on the results of a clinical study.
Alcon has said that its Allegretto Wave Eye-Q excimer laser combines proprietary wavefront-optimized PerfectPulse Technology, precise laser control and unparalleled speed for the most advanced laser technology in LASIK surgery. Alcon has acquired the US rights to the technology through the acquisition of assets from WaveLight AG in February 2008.
Steven Straus, CEO of LCA-Vision, said: “LasikPlus recently completed a contralateral, prospective, randomized study measuring surgical outcomes on a variety of excimer lasers, including the most recently FDA-approved laser, the Allegretto Wave Eye-Q. The Allegretto Wave Eye-Q excimer laser performed well on our evaluation criteria, leading to our decision to reduce our laser platforms from three to two and to expand our relationship with Alcon.”